Sitemap
December 08, 2012 Articles
Filter by Available Specialty
- Arsenic trioxide plus ATRA comparable to standard regimen for APL
- Combination of ibrutinib and rituximab produced high response rates in high-risk CLL
- Genotype may reduce toxicity in pediatric African-American and Asian patients with AML
- Ibrutinib associated with high response rates in patients with CLL